April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Rates of Visual Field (VF) Progression in Pigmentary Glaucoma (PG) and Juvenile Primary Open Angle Glaucoma (JPOAG)
A. Vaccaro; E. Kim; C. G. V. de Moraes; C. C. Teng; C. Tello; R. Ritch; J. M. Liebmann
Author Affiliations & Notes
  • A. Vaccaro
    Ophthalmology, Einhorn Clinical Research Center, NY Eye and Ear Infirmary, New York, New York
    NYU School of Medicine, New York, New York
  • E. Kim
    Ophthalmology, Einhorn Clinical Research Center, NY Eye and Ear Infirmary, New York, New York
  • C. G. V. de Moraes
    Ophthalmology, Einhorn Clinical Research Center, NY Eye and Ear Infirmary, New York, New York
    NYU School of Medicine, New York, New York
  • C. C. Teng
    Ophthalmology, Einhorn Clinical Research Center, NY Eye and Ear Infirmary, New York, New York
    Department of Ophthalmology, New York Medical College, Valhalla, New York
  • C. Tello
    Ophthalmology, Einhorn Clinical Research Center, NY Eye and Ear Infirmary, New York, New York
    Department of Ophthalmology, New York Medical College, Valhalla, New York
  • R. Ritch
    Ophthalmology, Einhorn Clinical Research Center, NY Eye and Ear Infirmary, New York, New York
    Department of Ophthalmology, New York Medical College, Valhalla, New York
  • J. M. Liebmann
    Ophthalmology, Einhorn Clinical Research Center, NY Eye and Ear Infirmary, New York, New York
    NYU School of Medicine, New York, New York
  • Footnotes
    Commercial Relationships  A. Vaccaro, None; E. Kim, None; C.G.V. de Moraes, None; C.C. Teng, None; C. Tello, Diopsys, Inc., F; Alcon Laboratories, Inc., R; Allergan, Inc., R; R. Ritch, Carl Zeiss Meditec, Inc., F; Diopsys, Inc., F; Heidelberg Engineering, GmBH, F; Topcon, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Danube Pharmaceuticals, Inc., C; Pfizer Ophthalmics, Inc., C; J.M. Liebmann, Carl Zeiss Meditec, Inc., F; Diopsys, Inc., F; Heidelberg Engineering, GmbH, F; Optovue, INC., F; Topcon Medical Systems, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Diopsys, Inc., C; Optovue, Inc., C; Pfizer, Inc., C; Topcon Medical Systems, Inc., C.
  • Footnotes
    Support  Supported in part by the Myron and Andrea Kove Research Fund of the New York Glaucoma Research Institute, New York, NY and Glaucoma Research and Education fund of Lenox Hill Hospital, New York, NY (C
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4020. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Rates of Visual Field (VF) Progression in Pigmentary Glaucoma (PG) and Juvenile Primary Open Angle Glaucoma (JPOAG)
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      A. Vaccaro, E. Kim, C. G. V. de Moraes, C. C. Teng, C. Tello, R. Ritch, J. M. Liebmann; Rates of Visual Field (VF) Progression in Pigmentary Glaucoma (PG) and Juvenile Primary Open Angle Glaucoma (JPOAG). Invest. Ophthalmol. Vis. Sci. 2010;51(13):4020.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To compare the rates of VF progression in treated patients with PG and JPOAG.

Methods: : The charts of all patients seen in a glaucoma referral practice between 1999 and 2009 were reviewed. Only treated eyes with ≥8 SITA Standard 24-2 VF tests with a diagnosis of PG or JPOAG were included. Age at initial diagnosis, sex, refractive error, central corneal thickness (CCT), baseline VF mean deviation (MD) and IOP were recorded. Eyes with underlying conditions known to affect the VF were excluded. Automated pointwise linear regression analysis determined global and localized rates (dB/yr) of change. A VF series was considered progressing by two criteria: A) sensitive criterion: when at least one point showed a threshold sensitivity decline at a rate of ≥1.0 dB/yr with p<0.01; B) specific criterion: two adjacent points in the same hemifield using the above (A) criteria.

Results: : 59 JPOAG and 24 PG eyes were enrolled. JPOAG patients were older (47.5±12.0 vs 35.7±9.2 yrs, p<0.01) and more often female (58% vs 38%, p=0.15, but refractive error (-3.6±3.4 vs -4.2±4.0 D, p=0.49), number of VF tests (10.5±3.0 ±11.3±3.1, p=0.27), f/u time (105±47 vs 117±56 months, p=0.3), mean CCT (549.4±39.8 vs 530.5.±41.6 µm, p=0.06), mean IOP (15.4±3.5 vs 14.5±3.2 mmHg, p=0.3), and peak IOP (mean 20.3±4.8 vs 18.9±4.8 mmHg, p=0.23) were similar. In the univariate analysis, PG eyes showed faster global rates of VF change (mean -0.40±0.4 vs -0.20±0.6 dB/yr, p=0.02) and similar localized rates (mean, -2.2±0.7 dB vs -2.0±0.7 dB/yr, p=0.45) compared to JPOAG eyes (Mann-Whitney rank test), but the difference in global rates became non-significant after adjusting for age and CCT (p=0.5, ANCOVA). The numbers of eyes reaching a progression endpoint using both the sensitive (PG, 11/24 vs JPOAG, 18/59, p=0.21) and specific (PG, 7/24 vs JPOAG, 12/59 p=0.39) criteria were statistically similar between groups.

Conclusions: : PG and JPOAG share similar epidemiological features (age of onset, myopia) despite different pathogeneses. Yet when treated, both diseases tend to behave similarly regarding rates of VF progression.

Keywords: visual fields • optic nerve • clinical (human) or epidemiologic studies: risk factor assessment 
© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept